Clinical Trial Update: MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)

View source ↗

Summary

A clinical trial evaluating satisfaction with Rebif after initial treatment for multiple sclerosis was terminated. Results were posted on 2019-01-18.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis | Status: TERMINATED | Results posted: 2019-01-18